Carlos A. Alemany, MD

Medical Director (Clinical Research), Medical Oncologist

Cancer Research

Expertise of Carlos A. Alemany, MD

Biography: Carlos Alemany, MD is a board-certified hematology and oncology physician in Orlando. Dr. Alemany earned his medical degree from Ponce School of Medicine in Ponce, Puerto Rico. He went on to complete a residency at the Cleveland Clinic Foundation in Cleveland, OH, staying there to pursue a fellowship as well. Dr. Alemany specializes in breast cancer and genitourinary malignancies. As an established member of the medical community, Dr. Alemany has authored and co-authored multiple articles in peer-reviewed medical journals on the topics of breast and genitourinary cancer. In addition to that, he has also authored many other articles related to lung cancer, lymphoma, anemia, multiple myeloma, colon cancer and novel chemotherapy agents. An award-winning physician, Dr. Alemany has been recognized as one of the Best Doctors in America every year since 2009 by Best Doctors, Inc, and the Orlando Magazine for his dedication to research and superior patient health. He is an associate professor at the University of Central Florida, and he is fluent in both English and Spanish.
Education: Ponce School of Medicine, Ponce, Puerto Rico
Residency: The Cleveland Clinic Foundation, Cleveland, OH
Fellowship: The Cleveland Clinic Foundation, Cleveland, OH
Specialty: Medical Oncology
Board Certifications: American Board of Internal Medicine

Publications

Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

2022, ANNALS OF ONCOLOGY

View publication for "Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study"
Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood

2022, PLOS ONE

View publication for "Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood"
SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

2020, ANNALS OF ONCOLOGY

View publication for "SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer"

More sources loaded
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

2019, CLINICAL BREAST CANCER

View publication for "Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study"
A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer

2019, CANCER RESEARCH

View publication for "A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer"
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care

2015, JOURNAL OF ONCOLOGY PRACTICE

View publication for "Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care"
Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval

2015, JOURNAL OF ONCOLOGY PRACTICE

View publication for "Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval"
Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor

2015, CASE REPORTS IN ENDOCRINOLOGY

View publication for "Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor"
Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval

2014, JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

View publication for "Florida Initiative for Quality Cancer Care: Improvements in Breast Cancer Quality Indicators During a 3-Year Interval"
Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care.

2014, Journal of oncology practice

View publication for "Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care."

More Publication Information

Associated Clinical Trials for Carlos A. Alemany, MD

NCT06188559

BB-1701-G000-205 An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

This study is currently enrolling.

Associated Conditions: Breast Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

The purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
NCT06191744

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

This study is currently enrolling.

Associated Conditions: Lymphoma

Research Area: Cancer Research

Research Location: Orlando, Florida

The primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary...
NCT06072612

A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)

This study is currently enrolling.

Associated Conditions: Breast Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

The purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune...

More clinical trials loaded
NCT05508906

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer

This study is currently enrolling.

Associated Conditions: Breast Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

Participants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 negative (HER2)...
NCT04510597

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931)

This study is currently enrolling.

Associated Conditions: Kidney Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931)
NCT02954874

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.

This study is currently enrolling.

Associated Conditions: Breast Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

The purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects...
NCT01515787

A Phase II/III of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)

This study is currently enrolling.

Associated Conditions: Colorectal Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

[$] [Abbreviated - Closed] The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen...
NCT04529772

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R CHOP) in Subjects ≤70 Years with Previously Untreated Non-Germinal Center Diffuse Large B Cell Lymphoma

This study is not currently enrolling.

Associated Conditions: Leukemia

Research Area: Cancer Research

Research Location: Orlando, Florida

This study is being done to understand whether patients with a type of DLBCL known as non-germinal center diffuse large B-cell lymphoma (non-GCB DLBCL) will benefit from the addition of acalabrutinib...
NCT03233711

A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer

This study is not currently enrolling.

Associated Conditions: Anal Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy {(mitomycin-C and 5-fluorouracil 5(-RU) or capecitabine) or 5-FU and...